You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

196 Results
Guidelines and Advice
Status: Education and Information
ID: 22-1
May 2017
Guidelines and Advice
Status: Current
ID: PET 18
May 2017
Guidelines and Advice
Status: In-Review
ID: 3-8-4
Version: 2
May 2017
Statistical Reports
*/ For the most recent data, refer to the Ontario Cancer Screening Performance Report 2023.
May 2017
Cancer facts
May 2017
Drug
Other Name(s): Lynparza®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jan 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
capivasertib (Unfunded),
fulvestrant
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2025
Drug
Other Name(s): Padcev®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jan 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Enfortumab Vedotin - Previously Treated Advanced or Metastatic Urothelial Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
enfortumab vedotin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2025
Drug
Other Name(s): Columvi®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jan 2025
Drug
Other Name(s): Epkinly™
Quick Link(s): Drug Monograph, Patient Info Sheet
Jan 2025
Drug
Other Name(s): Tecvayli®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jan 2025

Pages